[en] Aldosterone plays an important role in the pathophysiology of heart failure. Aldosterone receptor blockade has been shown to reduce morbidity and mortality in human patients with advanced congestive left ventricular heart failure. This study was designed to assess the efficacy and tolerance of long-term low-dose spironolactone when added to conventional heart failure treatment in dogs with advanced heart failure. Eighteen client-owned dogs with advanced congestive heart failure due to either degenerative valve disease (n=11) or dilated cardiomyopathy (n=7) were included in this prospective, placebo-controlled, double-blinded, randomized clinical study. After initial stabilization including furosemide, angiotensin-converting enzyme inhibitors, pimobendan and digoxin, spironolactone at a median dose of 0.52 mg/kg (range 0.49-0.8 mg/kg) once daily (n=9) or placebo (n=9) was added to the treatment, and the dogs were reassessed 3 and 6 months later. Clinical scoring, echocardiography, electrocardiogram, systolic blood pressure measurement, thoracic radiography, sodium, potassium, urea, creatinine, alanine aminotransferase, aldosterone and aminoterminal atrial natriuretic propeptide were assessed at baseline, 3 and 6 months. Survival times were not significantly different between the two treatment groups. Spironolactone was well tolerated when combined with conventional heart failure treatment.
Disciplines :
Médecine vétérinaire & santé animale
Auteur, co-auteur :
Schuller, S.
Van Israël, N.
Vanbelle, S.
Clercx, Cécile ; Université de Liège - ULiège > Département clinique des animaux de compagnie et des équidés > Pathologie médicale des petits animaux
Mc Entee, Kathleen ; Université de Liège - ULiège > Département clinique des animaux de compagnie et des équidés > Pathologie médicale des petits animaux
Langue du document :
Anglais
Titre :
Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs
Date de publication/diffusion :
2011
Titre du périodique :
Journal of Veterinary Pharmacology and Therapeutics
BENCH study (1999) The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of multicenter prospective, randomized, double blinded, placebo controlled, long term, clinical trial. Journal of Veterinary Cardiology, 1, 7-18.
Bernay, F., Bland, J.M., Häggström, J., Baduel, L., Combes, B., Lopez, A. & Klaltsatos, V. (2010) Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. Journal of Veterinary Internal Medicine, 24, 331-341.
Berry, C. & McMurray, J.J. (2001) Serious adverse events experience by patients with chronic heart failure taking spironolactone. Heart, 85, E8.
Buchanan, J.W. & Bücheler, J. (1995) Vertebral scale system to measure canine heart size in radiographs. Journal of the American Veterinary Medical Association, 206, 459-489.
Calvert, C.A., Pickus, C.W., Jacobs, G.J. & Brown, J. (1997) Signalment, survival, and prognostic factors in Doberman pinschers with end-stage cardiomyopathy. Journal of Veterinary Internal Medicine, 11, 323-326.
CONSENSUS study group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian Enalapril Study group. New England Journal of Medicine, 316, 1429-1435.
COVE study (1995) Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study group. Journal of Veterinary Internal Medicine, 9, 243-252.
Dickstein, K., Abrahamsen, S. & Aarsland, T. (1998) Plasma N-terminal atrial natriuretic peptide predicts hospitalization in patients with heart failure. Scandinavian Cardiovascular Journal, 32, 361-364.
Ettinger, S.J., Benitz, A.M., Ericsson, G.F., Cifelli, S., Jernigan, A.D., Longhofer, S.L., Trimboli, W. & Hanson, P.D. (1998) Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The long-term investigation of Veterinary Enalapril (LIVE) study group. Journal of the American Veterinary Medical Association, 213, 1573-1577.
Guyonnet, J., Elliott, J. & Kaltsatos, V. (2009) A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dogs. Journal of Veterinary Pharmacology and Therapeutics, 33, 260-267.
Häggström, J., Hansson, K., Karlberg, B.E., Kvart, C. & Olsson, K. (1994) Plasma concentration of atrial natriuretic peptide in relation to severity of mitral regurgitation in Cavalier King Charles Spaniels. American Journal of Veterinary Research, 55, 698-703.
Hayashi, M., Tsutamoto, T., Wada, A., Tsutsui, T., Ishii, C., Ohno, K., Fujii, M., Taniguchi, A., Hamatani, T., Nozato, Y., Kataoka, K., Morigami, N., Ohnishi, M., Kinoshita, M. & Horie, M. (2003) Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation, 107, 2559-2565.
IMPROVE study (1995) Acute and short-term haemodynamic, echocardiographic and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of invasive multicenter prospective veterinary evaluation of enalapril. Journal of Veterinary Internal Medicine, 9, 234-242.
Juurlink, D.N., Mamdani, M.M., Lee, D.S., Kopp, A., Austin, P.C., Laupacis, A. & Redelmeier, D.A. (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. New England Journal of Medicine, 351, 543-551.
Karram, T., Abbasi, A., Keidar, S., Golomb, E., Hochberg, I., Winaver, J., Hoffman, A. & Abassi, Z. (2005) Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 289, H1351-H1358.
Katz, A.M. (2003) Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. Journal of Cellular and Molecular Medicine, 7, 1-10.
Lachin, J.M. & Foulkes, M.A. (1986) Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses of follow up, noncompliance, and stratification. Biometrics, 42, 507-519.
Levin, E.R., Gardner, D.G. & Samson, W.K. (1998) Natriuretic peptides. New England Journal of Medicine, 339, 321-328.
MacFadyen, R.J., Lee, A.F., Morton, J.J., Pringle, S.D. & Struthers, A.D. (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart, 82, 57-61.
O'Grady, M.R., Bonagura, J.D., Powers, J.D. & Herring, D.S. (2005) Quantitative cross-sectional echocardiography in the normal dog. Veterinary Radiology, 27, 34-49.
Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J. & Wittes, J. (1999) The effect of Spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341, 709-717.
Rousseau, M.F., Gurné, O., Duprez, D., Van Mieghem, W., Robert, A., Ahn, S., Galanti, L. & Ketelslegers, J.M. (2002) Belgian RALES Investigators. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. Journal of the American College of Cardiology, 40, 1596-1601.
Schiller, N.B., Shah, P.M., Crawford, M., DeMaria, A., Devereux, R., Feigenbaum, H., Gutgesell, H., Reichek, N., Sahn, D. & Schnittger, I. (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. Journal of the American Society for Echocardiography, 2, 358-367.
Smith, P.J., French, A.T., Van Israël, N., Smith, S.G., Swift, S.T., Lee, A.J., Corcoran, B.M. & Dukes-McEwan, J. (2005) Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. Journal of Small Animal Practice, 46, 121-130.
Struthers, A.D. (2004) The clinical implications of aldosterone escape in congestive heart failure. European Journal of Heart Failure, 6, 539-545.
Suzuki, G., Morita, H., Mishima, T., Sharov, V.G., Todor, A., Tanhehco, E.J., Rudolph, A.E., McMahon, E.G., Goldstein, S. & Sabbah, H.N. (2002) Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation, 106, 2967-2972.
Swedberg, K., Eneroth, P., Kjekshus, J. & Wilhelmsen, L. (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation, 82, 1730-1736.
Thomason, J.D., Rockwell, J.E., Fallaw, T.K. & Calvert, C.A. (2007) Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease. Journal of Veterinary Cardiology, 11, 103-108.
Tidholm, A., Häggström, J. & Hansson, K. (2001) Effects of dilated cardiomyopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs. American Journal of Veterinary Research, 62, 961-967.
Van de Wal, R.M., Plokker, H.W., Lok, D.J., Boomsma, F., van der Horst, F.A., van Veldhuisen, D.J., van Gilst, W.H. & Voors, A.A. (2006) Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. International Journal of Cardiology, 106, 367-372.
Zannad, F., Alla, F., Dousset, B., Perez, A. & Pitt, B. (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation, 102, 2700-2706.
